# US 2017/0304314 A1 · Dosage regiment of ferric maltol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0304314 A1
- Document ID: US20170304314A1
- Status: Published application
- Kind: A1
- Application number: 15/520,753
- Filed: 2015-10-21
- Published: 2017-10-26
- Earliest claimed: 2014-10-21
- Assignees: Iron Therapeutics Holdings AG
- Applicants: Iron Therapeutics Holdings AG
- Inventors: Nicholas Mallard; Carl Andrew Sterritt; Julian David Howell
- Web page: https://patentgrep.com/patent/US20170304314A1

## CPC

- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 7/06: Antianaemics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a dosage regimen of ST10 (ferric maltol) for use in the treatment of patients suffering from iron deficiency with or without anaemia. The invention specifically relates to use of ST10 wherein the dose is between 40 mg and 90 mg twice daily.

## Claims

### Claim 1

A method of treating or preventing iron deficiency in a subject with or without anaemia, comprising orally administering to the subject a 40 mg to 90 mg dose of ST10 twice daily.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the ST10 dose is 60 mg to 90 mg.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the ST10 dose is 65 mg to 90 mg.

### Claim 4 (depends on 1)

The method according to claim 1 wherein the ST10 dose is 90 mg.

### Claim 5 (depends on 1)

The method according to claim 1 wherein the ST10 dose is 60 mg.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the ST10 dose is administered on two separate occasions during the waking hours.

### Claim 7 (depends on 6)

The method according to claim 6 wherein the ST10 dose is administered on an empty stomach.

### Claim 8 (depends on 4)

The method according to claim 4 wherein the ST10 90 mg dose is administered orally once daily.

### Claim 9 (depends on 1)

The method according to claim 1 wherein the ST10 dose is administered for up to a 16 week period.

### Claim 10 (depends on 1)

The method according to claim 1 wherein the ST10 dose is administered indefinitely as a maintenance dose.

### Claim 11 (depends on 1)

The method according to claim 1 wherein the ST10 dose is administered orally every two, three, four, five, six or seven days.

### Claim 12 (depends on 1)

The method according to claim 1 wherein iron deficiency is iron deficiency with anaemia.

### Claim 13 (depends on 12)

The method according to claim 12 wherein iron deficiency with anaemia is selected from chronic kidney disease (CKD), Systemic Lupus (SLE), rheumatoid arthritis, haematological cancers (e.g. Hodgkin's disease), chronic bacterial infection (e.g. osteomyelitis), viral hepatitis, HIV, AIDS, diseases of the gastrointestinal tract for example inflammatory bowel diseases (IBD).

### Claim 14 (depends on 13)

The method according to claim 13 wherein the inflammatory bowel disease is selected from Crohn's disease and ulcerative colitis.

### Claim 15 (depends on 1)

The method according to claim 1 wherein iron deficiency with or without anaemia is selected from active inflammatory disease or acute chronic inflammation.

### Claim 16

(canceled)
